Julian C. van Capelleveen

1.6k total citations · 1 hit paper
16 papers, 925 citations indexed

About

Julian C. van Capelleveen is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Julian C. van Capelleveen has authored 16 papers receiving a total of 925 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 9 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Julian C. van Capelleveen's work include Lipoproteins and Cardiovascular Health (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Cholesterol and Lipid Metabolism (5 papers). Julian C. van Capelleveen is often cited by papers focused on Lipoproteins and Cardiovascular Health (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers) and Cholesterol and Lipid Metabolism (5 papers). Julian C. van Capelleveen collaborates with scholars based in Netherlands, United States and United Kingdom. Julian C. van Capelleveen's co-authors include Erik S.G. Stroes, Joseph L. Witztum, Sotirios Tsimikas, Nicholas J. Viney, Stanley T. Crooke, Richard S. Geary, Shuting Xia, Rosie Z. Yu, Rosanne M. Crooke and Joseph A. Tami and has published in prestigious journals such as The Lancet, Circulation Research and Journal of the American Society of Nephrology.

In The Last Decade

Julian C. van Capelleveen

16 papers receiving 909 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

2016 544 citations Nicholas J. Viney, Julian C. van Capelleveen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julian C. van Capelleveen Netherlands	13	608	330	293	204	175	16	925
Tiziana Sampietro Italy	18	594 1.0×	299 0.9×	356 1.2×	156 0.8×	195 1.1×	75	1.1k
Gabriel P. Lasala United Kingdom	10	690 1.1×	184 0.6×	388 1.3×	161 0.8×	266 1.5×	14	1.0k
Toshinori Higashikata Japan	17	642 1.1×	233 0.7×	343 1.2×	291 1.4×	200 1.1×	34	1.1k
Fatima Akdim Netherlands	12	424 0.7×	311 0.9×	239 0.8×	164 0.8×	190 1.1×	24	871
Ursula Kassner Germany	17	535 0.9×	193 0.6×	206 0.7×	115 0.6×	98 0.6×	63	765
Barbara Sjouke Netherlands	19	1.1k 1.8×	306 0.9×	462 1.6×	337 1.7×	165 0.9×	35	1.4k
Randall B. Graham United States	9	821 1.4×	165 0.5×	154 0.5×	132 0.6×	316 1.8×	14	1.4k
JoAnn Flaim United States	10	848 1.4×	366 1.1×	440 1.5×	383 1.9×	467 2.7×	16	1.4k
Shazia Ali United States	9	696 1.1×	548 1.7×	353 1.2×	283 1.4×	75 0.4×	37	1.0k
Ashley Brooks United Kingdom	8	377 0.6×	117 0.4×	269 0.9×	119 0.6×	370 2.1×	12	927

Countries citing papers authored by Julian C. van Capelleveen

Since Specialization

Citations

This map shows the geographic impact of Julian C. van Capelleveen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian C. van Capelleveen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian C. van Capelleveen more than expected).

Fields of papers citing papers by Julian C. van Capelleveen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian C. van Capelleveen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian C. van Capelleveen. The network helps show where Julian C. van Capelleveen may publish in the future.

Co-authorship network of co-authors of Julian C. van Capelleveen

This figure shows the co-authorship network connecting the top 25 collaborators of Julian C. van Capelleveen. A scholar is included among the top collaborators of Julian C. van Capelleveen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian C. van Capelleveen. Julian C. van Capelleveen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Capelleveen, Julian C. van, Jeffrey Kroon, Jorge Peter, et al.. (2020). Genetic variants in SUSD2 are associated with the risk of ischemic heart disease. Journal of clinical lipidology. 14(4). 470–481. 3 indexed citations

Oldoni, Federico, Julian C. van Capelleveen, Justina C. Wolters, et al.. (2018). Naturally Occurring Variants in LRP1 (Low-Density Lipoprotein Receptor–Related Protein 1) Affect HDL (High-Density Lipoprotein) Metabolism Through ABCA1 (ATP-Binding Cassette A1) and SR-B1 (Scavenger Receptor Class B Type 1) in Humans. Arteriosclerosis Thrombosis and Vascular Biology. 38(7). 1440–1453. 14 indexed citations

Capelleveen, Julian C. van, Sang Rok Lee, Rutger Verbeek, et al.. (2018). Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of clinical lipidology. 12(6). 1493–1501.e11. 9 indexed citations

Capelleveen, Julian C. van, Andrea E. Bochem, S. Matthijs Boekholdt, et al.. (2017). Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association. 6(8). 13 indexed citations

Capelleveen, Julian C. van, Sophie J. Bernelot Moens, Xiaohong Yang, et al.. (2017). Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis Thrombosis and Vascular Biology. 37(6). 1206–1212. 57 indexed citations

Viney, Nicholas J., Julian C. van Capelleveen, Richard S. Geary, et al.. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 388(10057). 2239–2253. 544 indexed citations breakdown →

Capelleveen, Julian C. van, John J.P. Kastelein, Aeilko H. Zwinderman, et al.. (2016). Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. Journal of clinical lipidology. 10(5). 1137–1144.e3. 33 indexed citations

Motazacker, M. Mahdi, Julian C. van Capelleveen, Marion Weber‐Boyvat, et al.. (2016). A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacity. Atherosclerosis. 249. 140–147. 26 indexed citations

Moens, Sophie J. Bernelot, Simone L. Verweij, Fleur M. van der Valk, et al.. (2016). Arterial and Cellular Inflammation in Patients with CKD. Journal of the American Society of Nephrology. 28(4). 1278–1285. 49 indexed citations

10.

Capelleveen, Julian C. van, et al.. (2015). Current therapies for lowering lipoprotein (a). Journal of Lipid Research. 57(9). 1612–1618. 74 indexed citations

11.

Motazacker, M. Mahdi, Julian C. van Capelleveen, Suthesh Sivapalaratnam, et al.. (2015). A rare variant in MCF2L identified using exclusion linkage in a pedigree with premature atherosclerosis. European Journal of Human Genetics. 24(1). 86–91. 12 indexed citations

12.

Capelleveen, Julian C. van, Ruud S. Kootte, G. Kees Hovingh, & Andrea E. Bochem. (2015). Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency. Journal of clinical lipidology. 9(3). 396–399. 5 indexed citations

13.

Capelleveen, Julian C. van, H. Bryan Brewer, John J.P. Kastelein, & G. Kees Hovingh. (2014). Novel Therapies Focused on the High-Density Lipoprotein Particle. Circulation Research. 114(1). 193–204. 28 indexed citations

14.

Moens, Sophie J. Bernelot, Julian C. van Capelleveen, & Erik S.G. Stroes. (2014). Inhibition of ApoCIII. Current Opinion in Lipidology. 25(6). 418–422. 18 indexed citations

15.

Capelleveen, Julian C. van, Geesje M. Dallinga‐Thie, Alinda W.M. Schimmel, et al.. (2013). Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. Clinical Genetics. 85(5). 433–440. 18 indexed citations

16.

Capelleveen, Julian C. van, Andrea E. Bochem, M. Mahdi Motazacker, G. Kees Hovingh, & John J.P. Kastelein. (2013). Genetics of HDL-C: A Causal Link to Atherosclerosis?. Current Atherosclerosis Reports. 15(6). 326–326. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact